The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Smallcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Catalyst Trusteeship Ltd, acting as Debenture Trustee, has reported the creation of an additional pledge over 28,36,811 equity shares (2.47%) of OneSource Specialty Pharma Ltd by Tenshi Pharmaceuticals Pvt Ltd. The pledge was created in multiple tranches between January 29, 2026 and March 27, 2026 to secure zero-coupon, unlisted, redeemable non-convertible debentures of up to ₹1,000 crore issued by Karuna Ventures Pvt Ltd, a group company of the pledgor. With this, the total shares pledged with the trustee now stand at 92,36,811 shares, or 8.06% of the company's paid-up share capital. Tenshi Pharmaceuticals continues to hold 2,10,89,714 shares (18.4%) in the company, and the pledgor is not classified as a promoter. The debenture trustee has no direct voting rights on the pledged shares.
This is a financing-related encumbrance by a non-promoter shareholder to back group-level borrowing, not a change in ownership or promoter stake. Shareholders should note that 8.06% of the company's equity is now pledged as collateral, which could create overhang risk if the borrowing entity defaults, but the equity base of the company remains unchanged.